Creative Biolabs prepares cancer cancer vaccines through tumor antigen, immune adjuvant, and the vector. Selection of appropriate target antigens, formulations, adjuvants, and delivery pathways are key factors for the success of cancer cancer vaccines. Our experts support cancer vaccine developers and manufacturers by providing advanced characterization programs. We provide comprehensive quality assurance expertise to help you meet and exceed quantity, stability, and purity.
In order to ensure the safety of the cancer vaccine, high standard identification of the test cancer vaccine was carried out from the following aspects:
The attenuation degree of live attenuated cancer vaccine should be considered firstly. Natural virus strains are usually artificially modified to obtain non-pathogenic and immunogenic strains.
It is very extremely crucial to detect allergens in cancer vaccines. By applying current methods, these cancer vaccines do not purify the virus and contain other antigens during cell culture.
Most inactivation methods are chemical inactivators, such as methanol.
With expert stability indicator analytical method development skills, we ensure that any changes in physical and chemical properties, structure, polymerization, biological activity, appearance, impurities, excipient degradation and seal interactions can be detected.
Techniques such as microarray and second-generation sequencing will extract new ideas for evaluating the effectiveness of cancer vaccines.
Fig.1 Cancer Vaccine manufacturing. (Kalbfleisch, 2018)
Creative Biolabs provides a wide range of technologies for you to choose, as shown in the table:
Table 1: Cancer Vaccine identity technologies.
As stated in the European community directive on infectious biologicals by risk group (2000/54ec), we have specialized laboratory facilities to handle class I and class II biologicals. A variety of fully integrated biosafety testing procedures are used in cancer vaccine identification.
Please feel free to contact us and get more detailed information.
For any technical issues or products/services related questions, please leave your contacts as below, and our team will contact you at earliest convenience to let you know how we can be involved in your projects.
Nanoparticle Tiny Tech for Programming T Cells: A novel technology to increase the efficiency and value of your CAR-T therapy project.LEARN MORE
End-to-end CAR Hybrid TCR (CHyT)-T Cell Therapy Development Services: A novel solution to engineer T cell to be a promising cellular therapy with the complete TCR without HLA dependence.LEARN MORE
TRAC-CAR-T Cell Development with CRISPR/Cas9 Technology: A novel technology to build more powerful CAR-T cells.LEARN MORE